Literature DB >> 23249527

Pain in end-stage renal disease: a frequent and neglected clinical problem.

Domenico Santoro1, Ersilia Satta, Salvatore Messina, Giuseppe Costantino, Vincenzo Savica, Guido Bellinghieri.   

Abstract

Pain is a major health problem in end-stage renal disease (ESRD) affecting half of the dialysis patients; most of them experience a moderate to severe degree of pain. Nevertheless, the impact of chronic pain and its consequences are often underestimated. Sources of pain related to the uremic environment are renal bone disease (osteitis fibrosa cystica, amyloidosis, osteomalacia), osteoarthritis, calcific uremic arteriolopathy and peripheral neuropathy. Moreover, comorbid conditions such as ischemic peripheral artery disease, diabetic neuropathy, osteopenia/ osteoporosis (due to long-standing hypertension, diabetes, or old age) result in various kinds of pain. Also the primary kidney disease (e.g. autosomal dominant polycystic kidney disease (ADPKD)) as well as performance of hemodialysis or peritoneal dialysis are important causes of pain. Potential consequences of persistent pain are disturbed sleep, weakened memory/attention, altered mood (anxiety and depressive disorder), impotence, poorer physical state, less social activities and consideration of withdrawal from dialysis. Consequently the health-related-quality of life (HRQOL) is diminished, associated with a higher morbidity and mortality. In the therapy of pain the WHO three-step analgesic ladder adapted for ESRD, was shown to be effective in dialysis patients. Of fundamental importance are various forms of non-pharmacological strategies including electrotherapy. Recently the so-called high tone external muscle stimulation (HTEMS) was very effective in the management of neuropathic pain in ESRD patients.

Entities:  

Mesh:

Year:  2013        PMID: 23249527

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  30 in total

Review 1.  From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; George Hajishengallis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2016-06-16       Impact factor: 3.144

Review 2.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

3.  Longitudinal associations of depressive symptoms and pain with quality of life in patients receiving chronic hemodialysis.

Authors:  Linda Y Belayev; Maria K Mor; Mary Ann Sevick; Anne Marie Shields; Bruce L Rollman; Paul M Palevsky; Robert M Arnold; Michael J Fine; Steven D Weisbord
Journal:  Hemodial Int       Date:  2014-11-18       Impact factor: 1.812

4.  Prescription Opioids for Pain Management in Patients on Dialysis.

Authors:  Beth Han; Wilson M Compton
Journal:  J Am Soc Nephrol       Date:  2017-11-06       Impact factor: 10.121

5.  Opioid Prescription, Morbidity, and Mortality in United States Dialysis Patients.

Authors:  Paul L Kimmel; Chyng-Wen Fwu; Kevin C Abbott; Anne W Eggers; Prudence P Kline; Paul W Eggers
Journal:  J Am Soc Nephrol       Date:  2017-09-21       Impact factor: 10.121

6.  Associations of depressive symptoms and pain with dialysis adherence, health resource utilization, and mortality in patients receiving chronic hemodialysis.

Authors:  Steven D Weisbord; Maria K Mor; Mary Ann Sevick; Anne Marie Shields; Bruce L Rollman; Paul M Palevsky; Robert M Arnold; Jamie A Green; Michael J Fine
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-31       Impact factor: 8.237

7.  Prescribing patterns of non-steroidal anti-inflammatory drugs in chronic kidney disease patients in the South African private sector.

Authors:  Willem P Meuwesen; Jesslee M du Plessis; Johanita R Burger; Martie S Lubbe; Marike Cockeran
Journal:  Int J Clin Pharm       Date:  2016-04-18

8.  Mortality in US Hemodialysis Patients Following Exposure to Wildfire Smoke.

Authors:  Yuzhi Xi; Abhijit V Kshirsagar; Timothy J Wade; David B Richardson; M Alan Brookhart; Lauren Wyatt; Ana G Rappold
Journal:  J Am Soc Nephrol       Date:  2020-07-16       Impact factor: 10.121

9.  Reactive dicarbonyl compounds cause Calcitonin Gene-Related Peptide release and synergize with inflammatory conditions in mouse skin and peritoneum.

Authors:  Anna K Becker; Andrea Auditore; Monika Pischetsrieder; Karl Messlinger; Thomas Fleming; Peter W Reeh; Susanne K Sauer
Journal:  J Biol Chem       Date:  2020-03-20       Impact factor: 5.157

Review 10.  A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease.

Authors:  Niek F Casteleijn; Folkert W Visser; Joost P H Drenth; Tom J G Gevers; Gerbrand J Groen; Marie C Hogan; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.